---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-101298"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2022-09-20T23:59:59+00:00"
generated_at: "2026-06-23T08:25:57.351005+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics terminates PERFECT study of Tyvaso for PH associated with COPD

## Summary
- DSMC recommended termination after routine safety and efficacy analysis.
- Study evaluated Tyvaso (treprostinil) Inhalation Solution for pulmonary hypertension with COPD.
- Company will review available data and share results with the scientific community.
- Tyvaso is already approved for PAH and PH-ILD; termination affects a potential label expansion.

## SEC filing metadata
- accession: 0001104659-22-101298
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2022-09-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000110465922101298/0001104659-22-101298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000110465922101298/tm2226246d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-101298
- JSON: https://secwatch.observer/filing/0001104659-22-101298.json
- Plain text: https://secwatch.observer/filing/0001104659-22-101298.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.